Glancy Prongay & Murray Announces the Filing of a Securities Class Action on Behalf of Kitov Pharmaceutical Holdings LTD Investors and Encourages Investors to Contact the Firm

LOS ANGELES--()--Glancy Prongay & Murray LLP (“GPM”) announces that a class action lawsuit has been filed on behalf of investors who purchased Kitov Pharmaceutical Holdings LTD (“Kitov” or the “Company”) (NASDAQ: KTOV) American Depository Receipts (“ADRs”) pursuant and/or traceable to the Company’s initial public offering on or about November 20, 2015 (the “IPO”) and/or between November 20, 2015 and February 3, 2017, inclusive (the “Class Period”). Kitov investors have until April 10, 2017 to file a lead plaintiff motion.

Investors suffering losses on their Kitov Pharmaceutical Holdings LTD investments are encouraged to contact Lesley Portnoy of GPM to discuss their legal rights in this class action at 310-201-9150 or by email to shareholders@glancylaw.com.

The class action Complaint filed in this lawsuit alleges that throughout the Class Period, Defendants made materially false and misleading statements regarding the Company's business, operational and compliance policies. Specifically, Defendants made false and/or misleading statements and/or failed to disclose that: (1) Kitov and its Chief Executive Officer ("CEO") Isaac Israel published misleading information concerning the conduct of the Company's clinical trials for its lead drug candidate KIT-302; and (2) consequently, Kitov's public statements were materially false and misleading at all relevant times.

On February 6, 2017, it was revealed that Kitov's CEO Isaac Israel had been detained by the Israeli Securities Authority for purportedly issuing misleading information about Kitov's recent clinical trial.

On this news, shares of Kitov fell over 11% on February 6, 2017. The very next day, NASDAQ halted Kitov's ADRs trading.

If you purchased shares of Kitov during the Class Period you may move the Court no later than April 4, 2017 to ask the Court to appoint you as lead plaintiff if you meet certain legal requirements. To be a member of the Class you need not take any action at this time; you may retain counsel of your choice or take no action and remain an absent member of the Class. If you wish to learn more about this action, or if you have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Lesley Portnoy, Esquire, of GPM, 1925 Century Park East, Suite 2100, Los Angeles California 90067 at 310-201-9150, Toll-Free at 888-773-9224, by email to shareholders@glancylaw.com, or visit our website at http://glancylaw.com. If you inquire by email please include your mailing address, telephone number and number of shares purchased.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

Contacts

Glancy Prongay and Murray LLP, Los Angeles
Lesley Portnoy, 310-201-9150 or 888-773-9224
https://www.glancylaw.com
shareholders@glancylaw.com

Release Summary

Glancy Prongay & Murray Announces the Filing of a Securities Class Action on Behalf of Kitov Pharmaceutical Holdings LTD Investors and Encourages Investors to Contact the Firm

#Hashtags

Contacts

Glancy Prongay and Murray LLP, Los Angeles
Lesley Portnoy, 310-201-9150 or 888-773-9224
https://www.glancylaw.com
shareholders@glancylaw.com